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Hepatogastroenterology Unit, CHU Timone, Marseille, France Hepatitis C virus (HCV) infection is associated with reduced patient survival following combined liver-kidney transplantation (LKT). The aim of this study was to assess the efficacy and safety of second-generation direct-acting antivirals (DAAs) in this difficultto-treat population. The ANRS CO23 "Compassionate use of Protease Inhibitors in Viral C Liver Transplantation" (CUPILT) study is a prospective cohort including transplant recipients with recurrent HCV infection treated with DAAs. The present work focused on recipients with recurrent infection following LKT. The study population included 23 patients. All patients received at least one NS5B inhibitor (sofosbuvir) in their antiviral regimen an average of 90 months after LKT. Ninety-six percent of recipients achieved a sustained virological response (SVR) at week 12 (SVR12). In terms of tolerance, 39% of recipients presented with at least one serious adverse event. None of the patients experienced acute rejection during therapy and there were no deaths during follow-up. The glomerular filtration rate (GFR) decreased significantly from baseline to the end of therapy. However, this study did not show that the decline in GFR persisted over time or that it was directly related to DAAs. The DAA-based regimen is well tolerated with excellent results in terms of efficacy. It will become the gold standard for the treatment of recurrent HCV following LKT.
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| INTRODUCTION
Severe hepatitis C virus (HCV)-related liver diseases (decompensated cirrhosis and especially hepatocellular carcinoma) remain a major indication for liver transplantation (LT) in most centers worldwide. is accelerated compared to nontransplant patients. 6, 7 The recurrence of HCV infection following isolated LT or kidney transplantation (KT) negatively influences both graft and patient survival.
5-10
Until recently, antiviral treatment of transplant recipients with recurrent HCV infection was limited to the use of first-generation protease inhibitors (boceprevir-telaprevir) following LT increased the sustained virological response (SVR) at 24 weeks to 47% in genotype 1
patients, but was associated with a high rate of serious adverse events (SAEs), and concerns about interactions with immunosuppressive drugs. 11, 12 Since 2013, the use of second-generation direct-acting antivirals (DAAs) has provided major progress in isolated LT recipients with recurrent HCV (whatever the stage of liver fibrosis) and in previously "difficult-to-treat" patients with fibrosing cholestatic hepatitis. [13] [14] [15] An SVR 12 weeks after treatment was obtained in more than 90% of cases in all subpopulations, with fewer adverse events than in previous studies. Recent published studies have shown that second-generation oral DAAs also effectively treated HCV infection following isolated KT, with a low rate of treatment-related side effects. [16] [17] [18] These reports suggest that the outcome of LKT recipients treated with DAAs should be favorable. However, existing data are limited to a recent observational retrospective study including 7 LKT patients. 18 This is a specific population that has received two grafts and is obviously more likely to present with organ dysfunction and/or have a higher rate of side effects than patients with LT or KT alone. Thus a prospective study is needed to provide robust data on the safety and efficacy of DAAs in these patients.
The ANRS C023 "Compassionate use of Protease Inhibitors in Viral 
| PATIENTS AND METHODS

| Patients and study design
The was performed at the investigator's discretion.
| Efficacy assessments
In this study, plasma HCV RNA levels were quantified using the The primary endpoint was the proportion of patients who achieved undetectable HCV RNA levels or an SVR at FUW12 after treatment discontinuation (SVR12). Secondary endpoints included viral kinetics, and on-treatment (W4, W8, and W12), EOT, and FUW4, FUW12, and FUW24 response rates. Data on survival and liver and kidney functions were reported at FUW48. Virological failures were also reported.
Viral breakthrough and relapse were defined as plasma HCV RNA levels above the LLOQ after achieving a level below the LLOQ during treatment and EOT, respectively.
| Safety assessments
Data were collected for the following adverse events: SAEs, as de- 
20,21
Decisions to reduce, interrupt, or discontinue RBV because of toxic effects were based on the drug manufacturer's labeling. The investigators were encouraged to manage all adverse events according to guidelines issued by the French Association for the Study of the Liver (AFEF). 
| Statistical analysis
Statistical analyses were performed using SAS statistical software (SAS 
| RESULTS
| Baseline demographic and clinical characteristics
Twenty-three liver-kidney transplant recipients treated with DAAs were included in the present study between October 2013 and December 2015. The baseline characteristics of these recipients are presented in Table 3 shows the virological response during and after DAA therapy in the entire population and in relation to the use of RBV. This patient had HCV genotype 3a with baseline viral load of 7.27 log.
| Treatment efficacy
Variables Global (n = 23) RBV+ (n = 10) RBV− (n = 13) P T A B L E 4 Safety profile of antiviral therapy according to RBV use
AE
| Safety
Adverse events were common and occurred in 20 recipients (87.0%), although most were mild to moderate. The most common adverse event was anemia ( Table 4) . As expected, anemia was more frequent in recipients treated with RBV (80.0% vs 23.1% without; P = .0123).
In recipients treated with RBV, the dose of RBV was reduced and then discontinued for 2 recipients, only reduced for 4 recipients, and 
| Kinetics of renal function
In the overall population, there was a moderate but significant decrease in estimated GFR (eGFR) values between baseline and EOT (from 52.5 ± 29.2 to 46.9 ± 28.5 mL/min; P = .027) and between baseline and FUW12 (52.5 ± 29.2 to 47.2 ± 27 mL/min; P = .0039).
To determine this unexpected effect, we evaluated the potential cause of impaired eGFR. First, the daily dose of calcineurin inhibi- −0.56 ± 1.04 mL/min/month, P = .005) but not during (−0.27 ± 1.47 mL/min/month vs −0.29 ± 0.59 mL/min/month, P = .9) and after DAA therapy (−0.42 ± 1.32 mL/min/month vs −0.16 ± 1.17 mL/ min/month, P = .6) (Figure 4 ). The variation in kinetics in the entire population before, during, and after therapy was not statistically significant (mean GFR variation +0.28 ± 1.85 mL/min/month vs −0.28 ± 1.04 vs −0.27 ± 1.21, P = .35). Finally, we determined the individual slope of GFR before, during, and after DAA therapy ( Figure 5 ). The slope of most of the recipients with a positive slope before DAAs (83.3%) worsened >50% during treatment. However, after therapy the slope was worse >50% in only 3 recipients (30%) and the slope reversed in most. The slope was only worsened in 4 recipients with a negative slope before DAAs after DAA therapy.
| Follow-up
All LKT patients except one were alive at FUW48. One patient died between FUW24 and FUW48 from de novo skin carcinoma. At Hemodialysis was necessary throughout the study and until kidney retransplantation.
| DISCUSSION
Treating liver transplant recipients with an all-oral, interferon-free, antiviral regimen is now the standard of care. [13] [14] [15] To our knowl- Despite their renal metabolism, these inhibitors can be used in patients with CKD without safety concerns. 24 Safety was carefully investigated in our study population. In our cohort, the SAE reached 39%, most frequently anemia followed by infection with favorable outcomes. As expected, RBV use was associated with lower hemoglobin levels, a higher rate of anemia, erythropoietin, and red blood cell transfusions as well as the need for dose reduction. RBV administration is still a question because there was no significant difference in SVR between patients who did or did not receive RBV, whereas the tolerance was markedly worse in the former.
Finally, there was a small but significant reduction in GFR during treatment (from 52.5 to 46.9 mL/min between baseline and EOT) observed in the study cohort. No correlation was found with RBV use or daily doses of calcineurin inhibitors. Moreover, no significant variations in mean GFR were found between the periods before, during, and after therapy. Individual analysis of the slope of GFR showed that most recipients who presented a worsening of the slope had a negative slope before starting therapy. When worsening occurred during therapy this was reversed after therapy stopped. Finally, the GFR slope worsened in only a minority of recipients (n = 3) after therapy. Thus our study did not show that the decline in GFR persisted over time and was directly related to DAAs. These positive results are similar to those in the CORAL-I and SOLAR-1 trials that report DAA use following LT. In the CORAL-I study, mean creatinine clearance was 90.5 ml per minute at baseline and 85.9 ml per minute at week 24. None of the patients had a creatinine clearance of less than 50 ml per minute during treatment. 25 In the SOLAR-1 study there was no specific assessment of GFR kinetics. However, only one patient experienced an episode of acute renal failure in the cohort of 229 transplanted patients. 26 Further studies are needed to investigate the predictive factors of renal impairment during antiviral therapy. Other studies from the ANRS CO23 CUPILT cohort investigating pharmacokinetic changes and renal function are ongoing. A final report of the entire cohort will be also published.
In conclusion, the combination SOF ± NS5a inhibitor ± RBV for 12 or 24 weeks resulted in an SVR12 rate of 95.7% in LKT recipients. Overall, this regimen was safe and well tolerated. DAA regimens could become the gold standard for the treatment of recurrent HCV infection following LKT, allowing earlier treatment of patients before the development of graft fibrosis and CKD. This approach could help eradicate HCV infection in this specific population at high risk of both severe liver and kidney diseases and life-threatening events, in whom treatment guidelines are still awaited.
